Abstract
BackgroundErlotinib, gefitinib and crizotinib are tyrosine kinase inhibitors (TKIs) used in the treatment of non-small cell lung cancer (NSCLC). Their hepatic metabolism involves several cytochrome p450 isoenzymes, making them susceptible...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have